Fennec (NASDAQ: FENC) CCO acquires 168 newly released shares

Rhea-AI Filing Summary

FENNEC PHARMACEUTICALS INC. Chief Commercial Officer Terry L. Evans acquired 168 Common Shares through an exercise or conversion of a derivative security at a stated price of $0.00 per share. A footnote explains these represent shares released from restriction from shares awarded on 3/28/2025. Following this transaction, Evans directly holds 20,847 Common Shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Evans Terry L

Role Chief Commercial Officer

Type	Security	Shares	Price	Value
Exercise	Common Shares	168	$0.00	--

Holdings After Transaction: Common Shares — 20,847 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares acquired: 168 shares Transaction price per share: $0.00 per share Shares owned after transaction: 20,847 shares

3 metrics

Shares acquired 168 shares Exercise or conversion of derivative security

Transaction price per share $0.00 per share Derivative-related share acquisition

Shares owned after transaction 20,847 shares Direct Common Shares held by Terry L. Evans

Key Terms

Exercise or conversion of derivative security, Common Shares, Chief Commercial Officer, shares released from restriction

4 terms

Exercise or conversion of derivative security financial

"transaction_code_description: Exercise or conversion of derivative security"

Common Shares financial

"security_title: Common Shares"

Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.

Chief Commercial Officer financial

"officer_title: Chief Commercial Officer"

A chief commercial officer (CCO) is the senior executive responsible for a company’s revenue-generating activities, including sales, marketing, pricing, customer relationships and business development. Think of the CCO as the head coach who builds the game plan to win customers and grow sales; their effectiveness affects how fast a company earns money, enters new markets and sustains profits, making the role a key signal for investors about future revenue and competitive strength.

shares released from restriction financial

"Represents shares released from restriction from shares awarded 3/28/2025."

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Evans Terry L

(Last) (First) (Middle)

C/O FENNEC PHARMACEUTICALS, INC.

PO BOX 13628, 68 TW ALEXANDER DRIVE

(Street)

RESEARCH TRIANGLE PARK NORTH CAROLINA 27709

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
FENNEC PHARMACEUTICALS INC. [ FENC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares(1)	04/30/2026		M		168	A	$0	20,847	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares released from restriction from shares awarded 3/28/2025.

	/s/ Terry Evans	05/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did FENNEC PHARMACEUTICALS (FENC) report for Terry L. Evans?

FENNEC PHARMACEUTICALS reported that Chief Commercial Officer Terry L. Evans acquired 168 Common Shares. The shares came from an exercise or conversion of a derivative security, increasing his direct holdings to 20,847 Common Shares after the transaction.

How many FENC shares does Terry L. Evans own after this Form 4 transaction?

After this transaction, Chief Commercial Officer Terry L. Evans directly owns 20,847 Common Shares of FENNEC PHARMACEUTICALS. This total reflects the addition of 168 shares released from restriction that were originally awarded on March 28, 2025.

What was the price per share for Terry L. Evans’s latest FENC share acquisition?

The filing shows a transaction price per share of $0.00 for Terry L. Evans’s acquisition of 168 Common Shares. This indicates the shares resulted from an exercise or conversion of a derivative security rather than an open-market cash purchase.

What does the footnote in Terry L. Evans’s FENC Form 4 explain about the shares?

The footnote explains the 168 acquired Common Shares represent shares released from restriction from shares awarded on March 28, 2025. This suggests the transaction reflects previously granted equity becoming unrestricted, rather than a new market purchase of FENNEC PHARMACEUTICALS shares.

Is Terry L. Evans’s FENC transaction an open-market buy or a derivative exercise?

The Form 4 classifies the transaction with code M, indicating an exercise or conversion of a derivative security. Combined with the $0.00 transaction price, this shows the 168 shares were obtained through a derivative-related event, not an open-market purchase.